HT
LRMR icon

HAP Trading’s Larimar Therapeutics LRMR Stock Holding History

HAP Trading’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40,000
Closed -$105K – 776
2024
Q1 		$105K Buy
+40,000
New +$312K 0.01% 351

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

HAP Trading's LRMR Position: Q3 2025 in Review

HAP Trading increased its Larimar Therapeutics (LRMR) stake by 11% in Q3 2025, buying an estimated $93.7K and bringing the position to 262,776 shares worth $849K. The position accounts for 0.06% of the portfolio, ranked #198.

HAP Trading first reported a position in LRMR in Q1 2024 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

  • HAP Trading held 262,776 shares of Larimar Therapeutics worth $849K as of Q3 2025.
  • HAP Trading bought 25,000 Larimar Therapeutics shares in Q3 2025, an estimated $93.7K.
  • Larimar Therapeutics made up 0.06% of HAP Trading's portfolio in Q3 2025, its #198 holding.
  • HAP Trading first reported a position in Larimar Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on HAP Trading's 13F filing for Q3 2025, filed 12 Nov 2025.